Glooko touted data today from a six-month pilot program that evaluated the company’s remote diabetes management technology for people with Type II diabetes.
The pilot, which spanned from April until October of 2016, involved 50 Type II diabetes patients from San Diego, Calif.-based Sharp Rees-Stealy Medical Group. The medical group evaluated patient engagement, A1c levels, LDL, microalbumin and blood pressure throughout the course of the study.
By the end of the six months, participants doubled their daily blood glucose testing frequency and saw a 10% improvement in their blood glucose levels.
“We’re excited to see compelling evidence from this program,” Glooko CEO Rick Altinger said in prepared remarks. “One of the biggest challenges in diabetes care is leveraging the untapped data stored in disparate diabetes devices. A key aspect of this program was allowing patients to sync their data from their existing meters and receive actionable insights, mitigating hypo/hyper-glycemic events. We’re eager to continue this program to determine the impact Glooko can have on a larger patient population.”
Based on the results from the initial pilot program, Sharp Rees-Stealy plans to expand to a second phase with Glooko, the company reported.
“Due to its intuitive and highly functional interface, Glooko’s tools appeal to a large portion of our patient population,” Janet Appel, director of informatics and population health at Sharp Rees-Stealy, added.
“When patients use Glooko, they feel empowered and it inspires them to better manage their condition; it makes them feel like they’re in control. The results and product are just a couple of reasons why we decided to move forward with a larger patient population.”
